November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Updated Results with Mitazalimab as a first-line treatment for advance pancreatic cancer
Nov 13, 2024, 09:01

Updated Results with Mitazalimab as a first-line treatment for advance pancreatic cancer

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a recent article by Jean-Luc Van Laethem on LinkedIn:

“So, something exciting in metastatic pancreatic cancer. Small phase 2 data. Improvement in median OS upto 14.9 months. Will this work in phase 3 trial also? Let’s hope so.”

Title: Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

Authors: Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Karen Paula Geboes, Aurélien Lambert, Emmanuel Mitry, Philippe Alexandre Cassier, Jean-Frédéric Blanc, Lorenzo Pilla, Jaime Feliu Batlle, Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid, Inmaculada Gallego, Karin Enell Smith, Peter Ellmark, Yago Pico de Coaña, Sumeet Vijay Ambarkhane and Teresa Macarulla

Mitazalimab

Mitazalimab

Mitazalimab

 

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.

More posts featuring Amol Akhade.